Brainstorm Cell Therapeutics is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $1.75 |
|---|---|
| 52-week range | $1.09 - $4.70 |
| 50-day moving average | $1.65 |
| 200-day moving average | $2.84 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.64 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.745 from 2023-01-30
| 1 week (2023-01-25) | 20.34% |
|---|---|
| 1 month (2022-12-30) | 6.40% |
| 3 months (2022-11-01) | -50.85% |
| 6 months (2022-08-01) | -35.85% |
| 1 year (2022-02-01) | -45.81% |
|---|---|
| 2 years (2021-02-01) | -69.06% |
| 3 years (2020-01-31) | 4.07 |
| 5 years (2018-01-31) | 3.48 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -68.31% |
| Return on equity TTM | -193.43% |
| Profit margin | 0% |
| Book value | $0.04 |
| Market capitalisation | $53 million |
TTM: trailing 12 months
We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.
Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.
Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $1.0854 up to $4.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is -0.398. This would suggest that Brainstorm Cell Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Brainstorm Cell Therapeutics has bucked the trend.
Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.